Who may be considered
Eligibility depends on current FDA labeling, BMI, weight-related conditions, prior treatment, medications and risks. A prescriber must confirm that benefits outweigh risks and that the product and indication are appropriate.
Traducción automática para su comodidad. Para decisiones médicas,
confirme los detalles con nuestro equipo bilingüe.
GLP-1 Weight Management
Semaglutide for Medical Weight Management
Evidence-based, physician supervised. A clear, evidence-aware guide to candidacy, treatment, recovery, limitations and next steps.
Evidence reviewed July 30, 2026
Healthy Change
A plan built around your body—not a template
Physician-led guidance brings your goals, health history and realistic expectations into one thoughtful plan.
The Short Answer
What is Semaglutide for Medical Weight Management?
Semaglutide is a GLP-1 receptor agonist. FDA-approved Wegovy products are indicated for chronic weight management in eligible patients alongside reduced-calorie nutrition and increased physical activity, with additional labeled cardiovascular and liver-related indications depending on the current product labeling.
Candidacy
Who may—or may not—be a candidate
When treatment may not be appropriate
Semaglutide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 and with serious hypersensitivity to semaglutide. Pregnancy, pancreatitis history, severe gastrointestinal disease, gallbladder disease, diabetic retinopathy and interacting diabetes medicines require careful review.
At a Glance
Treatment facts
These are practical planning ranges, not promises. Your consultation determines the exact plan.
Treatment Time
Initial visit about 30–60 minutes; follow-ups are shorter
Comfort / Anesthesia
Weekly injection or other FDA-approved formulation as prescribed
Typical Downtime
No procedural downtime; gastrointestinal effects can limit activity
When Changes May Appear
Appetite or weight change evolves over weeks to months
How Long Results May Last
Long-term treatment may be needed; weight regain can occur after stopping
Treatments Commonly Considered
Ongoing titration and monitoring, not a short fixed series
Your Visit
What happens during treatment
Evaluate
The clinician reviews weight history, health conditions, medications, pregnancy plans and prior attempts, and orders appropriate labs.
Plan & treat
If eligible, an FDA-approved product is prescribed when accessible and clinically appropriate. Dose escalation follows product labeling and tolerability.
Review & follow up
Nutrition, activity, adverse effects and objective outcomes are monitored. Treatment is changed or stopped when risks, intolerance or lack of benefit outweigh benefit.
Informed Choice
Important risks, limitations and alternatives
Risks & limitations
Common effects include nausea, vomiting, diarrhea, constipation and abdominal pain. Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions, allergic reaction and low blood sugar with certain diabetes drugs. Current labeling includes a boxed warning related to thyroid C-cell tumors.
Alternatives to discuss
- Intensive lifestyle and nutrition treatment
- Another FDA-approved anti-obesity medication
- Tirzepatide when clinically appropriate
- Bariatric-surgery evaluation for eligible patients
Clinical Judgment
Why provider experience matters
Prescribing is only one part of safe obesity care. Experienced medical oversight verifies the product source, screens contraindications, manages titration and side effects, preserves lean mass and monitors when treatment should change.
Access & Cost
In-office versus telehealth
Consultations and follow-up may be in-office or by telehealth for patients physically located in Texas, North Carolina or South Carolina, subject to eligibility and law. Labs or in-person assessment may be required.
Pricing: Consultation required. Medication price varies by FDA-approved product, insurance coverage, pharmacy and dose. Identity Aesthetics does not promise coverage or a fixed medication cost.
Common Questions
Semaglutide for Medical Weight Management FAQ
No. Compounded drugs are not FDA-approved. They may be used only under applicable law and patient-specific clinical circumstances; FDA has warned about dosing errors, quality concerns and products using different salt forms.
Weight regain is common after stopping anti-obesity medication. Long-term planning should be discussed before starting.
Ozempic is approved for type 2 diabetes indications, while Wegovy products carry weight-management indications. Product selection must follow diagnosis, labeling and clinician judgment.
Sources & Medical Review